DE4309217A1 - Combination product of pantothenic acid or dexpanthenol + alpha -lipoic acid + vitamin E (muscular dystrophy, polyneuropathy, muscle atrophy, ataxia, new indication ( alpha -lipoic acid + pantothenic acid) Alzheimer's disease - Google Patents

Combination product of pantothenic acid or dexpanthenol + alpha -lipoic acid + vitamin E (muscular dystrophy, polyneuropathy, muscle atrophy, ataxia, new indication ( alpha -lipoic acid + pantothenic acid) Alzheimer's disease

Info

Publication number
DE4309217A1
DE4309217A1 DE19934309217 DE4309217A DE4309217A1 DE 4309217 A1 DE4309217 A1 DE 4309217A1 DE 19934309217 DE19934309217 DE 19934309217 DE 4309217 A DE4309217 A DE 4309217A DE 4309217 A1 DE4309217 A1 DE 4309217A1
Authority
DE
Germany
Prior art keywords
acid
alpha
lipoic acid
pantothenic acid
dexpanthenol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19934309217
Other languages
German (de)
Inventor
Margarethe Rabien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE19924201196 priority Critical patent/DE4201196C2/en
Priority claimed from DE19924201196 external-priority patent/DE4201196C2/en
Application filed by Individual filed Critical Individual
Priority to DE19934309217 priority patent/DE4309217A1/en
Publication of DE4309217A1 publication Critical patent/DE4309217A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2

Abstract

Combination product which contains at least alpha -lipoic acid + pantothenic acid (or dexpanthenol) + vitamin E as pharmaceutical for muscular dystrophy but also for ataxia, multiple sclerosis, polyneuropathy, muscle atrophy and similar disorders. New indication: Alzheimer's disease (medicament which contains at least alpha -lipoic acid and pantothenic acid or dexpanthenol).

Description

Medikament zur Verbesserung der Gehirnleistung bei der Alzheimer­ schen Krankheit und anderen Gehirnleistungskrankheiten mit den Kombinationen
6. α-Liponsäure + Pantothensäure
7. α-Liponsäure + Pantothensäure + Vitamin B1
Muskelschwundmedikament α-Liponsäure + Pantothonsäure ist be­ reits bekannt (G 92 00 543.8).Drug to improve brain performance in Alzheimer's disease and other brain disorders with the combinations
6. α-lipoic acid + pantothenic acid
7. α-lipoic acid + pantothenic acid + vitamin B1
Muscle loss medication α-lipoic acid + pantothonic acid is already known (G 92 00 543.8).

Bereits bekannt Velnacrine (amerikanisches Medikament) verhindert den Abbau von Acetylcholin im Gehirn und hilft so bei der Alzhei­ merschen Krankheit.Already known Velnacrine (American drug) prevents the breakdown of acetylcholine in the brain and thus helps with Alzhei human disease.

α-Liponsäure + Pantothensäure fördern den Aufbau von Acetyl­ cholin im Gehirn und verbessern so die Gehirnleistung bei der Alzheimerschen Krankheit und anderen Gehirnleistungskrankheiten.α-Lipoic acid + pantothenic acid promote the build-up of acetyl choline in the brain and thus improve brain performance in the Alzheimer's disease and other brain disorders.

Claims (1)

Mehrkomponentenmedikament (bzw. Mehrkomponentenpackung) gegen Polyneuropathie, Ataxie, Muskelatrophie usw. mit folgenden Kombinationen nach Hauptanmeldung P 42 01 196.5,
1. Pantothensäure (bzw. Dexpanthenol), α-Liponsäure
2. Vitamin B2-Komplex, α-Liponsäure
3. Pantothensäure (bzw. Dexpanthenol), α-Liponsäure, Vitamin B1, B6, B12
4. Pantothensäure (bzw. Dexpanthenol), α-Liponsäure, Pyridoxin (B6)
5. Komplex, αLiponsäure, Vitamin B1, B6, B12,
dadurch gekennzeichnet, daß es zur Verbesserung der Gehirnlei­ stung bei der Alzheimerschen Krankheit und anderen Gehirnlei­ stungskrankheiten die Kombinationen
6. α-Liponsäure und Pantothensäure
7. α-Liponsäure und Pantothensäure und Vitamin B1
enthält.Multi-component drug (or multi-component pack) for polyneuropathy, ataxia, muscle atrophy etc. with the following combinations according to main application P 42 01 196.5,
1. pantothenic acid (or dexpanthenol), α-lipoic acid
2. Vitamin B2 complex, α-lipoic acid
3. pantothenic acid (or dexpanthenol), α-lipoic acid, vitamins B1, B6, B12
4. pantothenic acid (or dexpanthenol), α-lipoic acid, pyridoxine (B6)
5. complex, α-lipoic acid, vitamins B1, B6, B12,
characterized in that it combinations to improve the brain performance in Alzheimer's disease and other brain performance disorders
6. α-lipoic acid and pantothenic acid
7. α-lipoic acid and pantothenic acid and vitamin B1
contains.
DE19934309217 1992-01-18 1993-01-22 Combination product of pantothenic acid or dexpanthenol + alpha -lipoic acid + vitamin E (muscular dystrophy, polyneuropathy, muscle atrophy, ataxia, new indication ( alpha -lipoic acid + pantothenic acid) Alzheimer's disease Withdrawn DE4309217A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE19924201196 DE4201196C2 (en) 1992-01-18 1992-01-18 Medicines used to treat polyneuropathy
DE19934309217 DE4309217A1 (en) 1992-01-18 1993-01-22 Combination product of pantothenic acid or dexpanthenol + alpha -lipoic acid + vitamin E (muscular dystrophy, polyneuropathy, muscle atrophy, ataxia, new indication ( alpha -lipoic acid + pantothenic acid) Alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19924201196 DE4201196C2 (en) 1992-01-18 1992-01-18 Medicines used to treat polyneuropathy
DE19934309217 DE4309217A1 (en) 1992-01-18 1993-01-22 Combination product of pantothenic acid or dexpanthenol + alpha -lipoic acid + vitamin E (muscular dystrophy, polyneuropathy, muscle atrophy, ataxia, new indication ( alpha -lipoic acid + pantothenic acid) Alzheimer's disease

Publications (1)

Publication Number Publication Date
DE4309217A1 true DE4309217A1 (en) 1994-07-28

Family

ID=25911053

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19934309217 Withdrawn DE4309217A1 (en) 1992-01-18 1993-01-22 Combination product of pantothenic acid or dexpanthenol + alpha -lipoic acid + vitamin E (muscular dystrophy, polyneuropathy, muscle atrophy, ataxia, new indication ( alpha -lipoic acid + pantothenic acid) Alzheimer's disease

Country Status (1)

Country Link
DE (1) DE4309217A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027968A1 (en) * 2000-06-08 2001-12-13 Asta Medica Ag Adjuvant therapy of dementia using alpha-lipoic acid or derivative, is effective in combination with antidementia or neurotransmission improving agents in improving cognitive function in e.g. Alzheimer's disease patients
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US7560447B2 (en) 2000-05-08 2009-07-14 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US7772217B2 (en) * 2000-05-08 2010-08-10 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US8377912B2 (en) 2000-05-08 2013-02-19 N. V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US8865687B2 (en) 2000-05-08 2014-10-21 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
DE10027968A1 (en) * 2000-06-08 2001-12-13 Asta Medica Ag Adjuvant therapy of dementia using alpha-lipoic acid or derivative, is effective in combination with antidementia or neurotransmission improving agents in improving cognitive function in e.g. Alzheimer's disease patients
WO2001093865A2 (en) * 2000-06-08 2001-12-13 Viatris Gmbh & Co. Kg Medicaments for treating dementia
WO2001093865A3 (en) * 2000-06-08 2002-07-25 Viatris Gmbh Medicaments for treating dementia

Similar Documents

Publication Publication Date Title
BR9808812A (en) Composition comprising crystalline, finely divided budesonide particles
BR9307719A (en) Atovaquone in the form of particles, microfluidized atovaquone particles, pharmaceutical composition, and methods for the preparation of atovaquone microfluidic particles and for the preparation of pharmaceutical compositions
BR9407720A (en) Compound pharmaceutical composition and process for the prevention or treatment of immunoregulatory disorders or diseases that comprise the administration of the compound
AR042262A2 (en) USE OF 8,9-DIHYDROESTRONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ATEROSCLEROSIS
IT1241996B (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISORDERS AND METHOD FOR ITS APPLICATION.
PT88985A (en) Process for the preparation of nasal and ophthalmic pharmaceutical compositions containing azelastine
BR9713141A (en) Pharmaceutical composition process and kit for the treatment or prevention of a physiological condition associated with an ischemic disorder related to thrombosis and a patient, use of pharmaceutically effective amounts of a compound with anti-xa activity and a platelet aggregating antagonist compound, product containing these compounds, and, use of these compounds.
IT1241997B (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISORDERS AND METHOD FOR ITS APPLICATION.
ES2153906T3 (en) USE OF INCENSE FOR THE TREATMENT OF ALZHEIMER'S DISEASE.
IL97796A0 (en) Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation
UA60352C2 (en) synthetic polysaccharides, a method for preparing thereof and pharmaceutical composition containing them
DE4309217A1 (en) Combination product of pantothenic acid or dexpanthenol + alpha -lipoic acid + vitamin E (muscular dystrophy, polyneuropathy, muscle atrophy, ataxia, new indication ( alpha -lipoic acid + pantothenic acid) Alzheimer's disease
DE60003175T2 (en) COMBINATION PRODUCT FOR TREATING MALARIA
DE10163667A1 (en) Use of deoxypeganine to treat clinical depression
KR970005283A (en) Use of sertraline to treat patients after myocardial infarction
GB9126874D0 (en) Medicaments
MW1291A1 (en) Medicaments for the treatment of toxo-plasmosis
ATE195868T1 (en) PHARMACEUTICAL COMPOSITIONS OF GALLIUM COMPLEXES OF 3-HYDROXY-4-PYRONES
GB9216859D0 (en) Medicaments
HUT60431A (en) Process for producing pharmaceutical compositions comprising naphthoquinone derivative and suitable for treating cryptosporidiosis
Leadbetter et al. Mood-stabilizing properties of lamotrigine: a review of data from controlled clinical trials
DE4301465A1 (en) Combination product especially for muscular dystrophy, but also treatment of polyneuropathy, MS, ataxia, muscle atrophy etc. with the combinations
DE102018007478A1 (en) Medicinal or nutritional supplements for the treatment and / or prophylaxis of joint diseases and / or inflammatory joint diseases
EP2606904A1 (en) Medicine or food supplement for treating and/or preventing joint ailments
KR960010013A (en) Analgesic effect synergistic composition consisting of analgesic drug and ginger extract treatment

Legal Events

Date Code Title Description
AF Is addition to no.

Ref country code: DE

Ref document number: 4201196

Format of ref document f/p: P

AF Is addition to no.

Ref country code: DE

Ref document number: 4201196

Format of ref document f/p: P

8141 Disposal/no request for examination